American Association for Cancer Research
10780432ccr141749-sup-134418_2_supp_2786679_ngnh2m.png (96.52 kB)

Supplementary Figure S4 from Integrating RAS Status into Prognostic Signatures for Adenocarcinomas of the Lung

Download (96.52 kB)
posted on 2023-03-31, 18:41 authored by Maud HW. Starmans, Melania Pintilie, Michelle Chan-Seng-Yue, Nathalie C. Moon, Syed Haider, Francis Nguyen, Suzanne K. Lau, Ni Liu, Arek Kasprzyk, Bradly G. Wouters, Sandy D. Der, Frances A. Shepherd, Igor Jurisica, Linda Z. Penn, Ming-Sound Tsao, Philippe Lambin, Paul C. Boutros

Supplementary Figure S4. Kaplan-Meier survival curve for a cohort of 549 adenocarcinoma patients stratified according to predicted RAS pathway activation status.



Purpose: While the dysregulation of specific pathways in cancer influences both treatment response and outcome, few current prognostic markers explicitly consider differential pathway activation. Here we explore this concept, focusing on K-Ras mutations in lung adenocarcinoma (present in 25%–35% of patients).Experimental Design: The effect of K-Ras mutation status on prognostic accuracy of existing signatures was evaluated in 404 patients. Genes associated with K-Ras mutation status were identified and used to create a RAS pathway activation classifier to provide a more accurate measure of RAS pathway status. Next, 8 million random signatures were evaluated to assess differences in prognosing patients with or without RAS activation. Finally, a prognostic signature was created to target patients with RAS pathway activation.Results: We first show that K-Ras status influences the accuracy of existing prognostic signatures, which are effective in K-Ras-wild-type patients but fail in patients with K-Ras mutations. Next, we show that it is fundamentally more difficult to predict the outcome of patients with RAS activation (RASmt) than that of those without (RASwt). More importantly, we demonstrate that different signatures are prognostic in RASwt and RASmt. Finally, to exploit this discovery, we create separate prognostic signatures for RASwt and RASmt patients and show that combining them significantly improves predictions of patient outcome.Conclusions: We present a nested model for integrated genomic and transcriptomic data. This model is general and is not limited to lung adenocarcinomas but can be expanded to other tumor types and oncogenes. Clin Cancer Res; 21(6); 1477–86. ©2015 AACR.

Usage metrics

    Clinical Cancer Research



    Ref. manager